RENE.L Regulatory News (RENE)

12 Feb 2007 13:00

ReNeuron Group plc12 February 2007 ReNeuron to Present at 2nd Annual Stem Cell Summit Guildford, UK, 12 February 2007: ReNeuron Group plc (LSE: RENE.L) todayannounces that its Founder and Chief Scientific Officer, Dr. John Sinden, willpresent an overview of the Company's leading edge stem cell technologies andprogrammes at the 2nd Annual Stem Cell Summit being held at the Wyndham atEmerald Plaza San Diego in San Diego, California. The presentation is scheduledfor Monday, February 12, 2007 at 2:45 PM PST. Utilizing its proprietary c-mycER(TAM) adult stem cell expansion platform,ReNeuron is developing groundbreaking cell therapy products. The Company iscurrently focused on cell therapy treatments designed to reverse the effects ofmajor diseases such as stroke, Parkinson's disease, diabetes and diseases of theretina. More information about the conference may be found at www.stemcellsummit.com. Inquiries: ReNeuronMichael Hunt, Chief Executive Officer Tel: 44 (0)1483 302 560John Sinden, Chief Scientific Officer Financial DynamicsJonathan Birt Tel: (212) 850-5634Robert Stanislaro Tel: (212) 850-5657 Notes to Editors ReNeuron is a leading, UK-based adult stem cell therapy business. It is applyingits novel stem cell platform technologies in the development of ground-breakingstem cell therapies to serve significant and unmet or poorly-met clinical needs.ReNeuron has used its c-mycERTAM technology to generate genetically stableneural stem cell lines. This technology platform has multi-national patentprotection and is fully regulated by means of a chemically-induced safetyswitch. Cell growth can therefore be completely arrested prior to in vivoimplantation. ReNeuron has filed for approval to commence initial clinical studies in the USwith its lead ReN001 stem cell therapy for chronic stroke disability. Thisrepresents the world's first such filing concerning a neural stem cell treatmentfor a major neurological disorder. There are an estimated 50 million strokesurvivors worldwide, approximately one half of which are left with permanentdisabilities. The annual health and social costs of caring for these patients isestimated to be in excess of £5 billion in the UK and in excess of US$50 billionin the US. ReNeuron has also generated pre-clinical efficacy data with its ReN005 stem celltherapy for Huntington's disease, a genetic and fatal neurodegenerative disorderthat affects around 1 in 10,000 people. This programme is in pre-clinicaldevelopment. In addition to its stroke and Huntington's disease programmes, ReNeuron isdeveloping stem cell therapies for Parkinson's disease, Type 1 diabetes anddiseases of the retina. ReNeuron has also leveraged its stem cell technologies into non-therapeuticareas - its ReNcell(TM) range of cell lines for use in research and in drugdiscovery applications in the pharmaceutical industry. ReNeuron's ReNcell(TM) CXand ReNcell(TM) VM neural cell lines are marketed worldwide under license byMillipore Corporation. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found atwww.reneuron.com. Data sources: UK Stroke Association, American Stroke Association. This announcement contains forward-looking statements with respect to thefinancial condition, results of operations and business achievements/performanceof ReNeuron and certain of the plans and objectives of management of ReNeuronwith respect thereto. These statements may generally, but not always, beidentified by the use of words such as "should", "expects", "estimates","believes" or similar expressions. This announcement also containsforward-looking statements attributed to certain third parties relating to theirestimates regarding the growth of markets and demand for products. By theirnature, forward-looking statements involve risk and uncertainty because theyreflect ReNeuron's current expectations and assumptions as to future events andcircumstances that may not prove accurate. A number of factors could causeReNeuron's actual financial condition, results of operations and businessachievements/performance to differ materially from the estimates made or impliedin such forward-looking statements and, accordingly, reliance should not beplaced on such statements. The terms 'ReNeuron', 'the Company' or 'the Group' used in this statement referto ReNeuron Group plc and/or its subsidiary undertakings, depending on thecontext. This information is provided by RNS The company news service from the London Stock Exchange